齐拉西酮合并碳酸锂治疗双相情感障碍躁狂发作的疗效对患者血清神经递质的影响
|
摘要
目的探讨齐拉西酮合并碳酸锂治疗双相情感障碍躁狂发作的临床疗效及对患者血清神经递质的影响。方法将本院2017年3月至2018年5月收治的78例躁狂症患者作为研究对象,按随机数字表法等分为实验组和对照组,治疗6周,1周1疗程,实验组采用齐拉西酮联合碳酸锂治疗,对照组则只给予碳酸锂治疗,评估两组患者在疗程结束后临床疗效、并发症以及6个月后复发率差异,同时,检测并分析两者治疗前和治疗6周后的血清神经递质去甲肾上腺素(NE)、5-羟色胺(5-HT)、多巴胺(DA)浓度。结果实验组的总有效率达97.44%,对照组仅为76.92%,两组差异比较有统计学意义(P<0.05),治疗后,两组血清中NE、5-HT、DA浓度均有所降低,但实验组下降更明显,与对照组相比差异具有统计学意义(P<0.05),同时,实验组并发症及6个月后复发率均显著低于对照组,两组差异比较有统计学意义(P<0.05)。结论对于双相情感障碍躁狂患者而言应用齐拉西酮合并碳酸锂治疗,能显著性降低血清神经递质浓度,患者精神状态恢复良好,疗效确切,不良反应少,疾病复发率低,值得进一步应用于临床。
Objective To investigate the clinical efficacy of ziprasidone combined with lithium carbonate in the treatment of manic episodes of bipolar disorder and its effect on serum neurotransmitters. Methods 78 cases of mania patients admitted to our hospital from March 2017 to May2018 were randomly divided into the experimental group and the control group according to the random number table method. The treatment was 6 weeks, One course of treatment per week. The test group was treated with ziprasidone combined with lithium carbonate, while the control group was treated with only lithium carbonate. The clinical efficacy, complications, and recurrence rate after 6 months of treatment were evaluated. Serum neurotransmitters, norepinephrine(NE), serotonin(5-HT), and dopamine(DA) concentrations before and after 6 weeks of treatment. Results The total effective rate of the experimental group was 97.44%, and the control group was only 76.92%. The difference between the two groups was statistically significant(P<0.05). After treatment, the concentrations of NE, 5-HT and DA in the serum of the two groups were all. The decrease was significant,but the decrease was more significant in the experimental group. There was a statistically significant difference compared with the control group(P<0.05). At the same time, the complications of the experimental group and the recurrence rate after 6 months were significantly lower than those of the control group. Group differences were statistically significant(P<0.05). Conclusion For patients with bipolar disorder madness, the use of ziprasidone combined with lithium carbonate can significantly reduce serum neurotransmitter concentration, the patient' s mental state recovers well, the curative effect is exact, the adverse reactions are less, and the disease recurrence rate is low. It is worth further application in the clinic.
Objective To investigate the clinical efficacy of ziprasidone combined with lithium carbonate in the treatment of manic episodes of bipolar disorder and its effect on serum neurotransmitters. Methods 78 cases of mania patients admitted to our hospital from March 2017 to May2018 were randomly divided into the experimental group and the control group according to the random number table method. The treatment was 6 weeks, One course of treatment per week. The test group was treated with ziprasidone combined with lithium carbonate, while the control group was treated with only lithium carbonate. The clinical efficacy, complications, and recurrence rate after 6 months of treatment were evaluated. Serum neurotransmitters, norepinephrine(NE), serotonin(5-HT), and dopamine(DA) concentrations before and after 6 weeks of treatment. Results The total effective rate of the experimental group was 97.44%, and the control group was only 76.92%. The difference between the two groups was statistically significant(P<0.05). After treatment, the concentrations of NE, 5-HT and DA in the serum of the two groups were all. The decrease was significant,but the decrease was more significant in the experimental group. There was a statistically significant difference compared with the control group(P<0.05). At the same time, the complications of the experimental group and the recurrence rate after 6 months were significantly lower than those of the control group. Group differences were statistically significant(P<0.05). Conclusion For patients with bipolar disorder madness, the use of ziprasidone combined with lithium carbonate can significantly reduce serum neurotransmitter concentration, the patient' s mental state recovers well, the curative effect is exact, the adverse reactions are less, and the disease recurrence rate is low. It is worth further application in the clinic.
引文
[1]盛承东,宋苏琪,李军,等.齐拉西酮辅助治疗青春期双相情感障碍Ⅰ型躁狂发作的疗效探讨[J].中国现代医学杂志,2015,25(19):72-75.
[2]黄悦琦,洪武,邱美慧,等.中国双相情感障碍不同躁狂发作亚型危险因素的现况调查[J].中国心理卫生杂志,2015,29(12):927-932.
[3]刘玉莲,尹冬青,吴炜,等.双相情感障碍患者病耻感特征及其与疾病严重程度的关系研究[J].中华护理杂志,2016,51(12):1413-1416.
[4]黄仕善,陶建青.双相情感障碍缓解期患者情境式交往训练的效果观察[J].护理学报,2016,23(9):68-71.
[5]郭振宇,刘勇,孙群星,等.齐拉西酮与碳酸锂对躁狂发作患者疗效及认知功能的影响[J].临床心身疾病杂志,2014,20(6):52-56.
[6]王雪莲.躁狂症经齐拉西酮治疗以及氯氮平联合碳酸锂治疗的效果对比[J].中国保健营养,2017,27(3):250.
[7]孙志国,杨巍,冯萍萍,等.广泛性焦虑症患者血清神经递质及凝血相关指标的变化分析[J].中国实用神经疾病杂志,2016,19(16):36-37.
[8]郭世锦.广泛性焦虑症患者的血清神经递质及凝血相关指标的变化情况分析[J].世界最新医学信息文摘,2016,16(31):54-55.
[2]黄悦琦,洪武,邱美慧,等.中国双相情感障碍不同躁狂发作亚型危险因素的现况调查[J].中国心理卫生杂志,2015,29(12):927-932.
[3]刘玉莲,尹冬青,吴炜,等.双相情感障碍患者病耻感特征及其与疾病严重程度的关系研究[J].中华护理杂志,2016,51(12):1413-1416.
[4]黄仕善,陶建青.双相情感障碍缓解期患者情境式交往训练的效果观察[J].护理学报,2016,23(9):68-71.
[5]郭振宇,刘勇,孙群星,等.齐拉西酮与碳酸锂对躁狂发作患者疗效及认知功能的影响[J].临床心身疾病杂志,2014,20(6):52-56.
[6]王雪莲.躁狂症经齐拉西酮治疗以及氯氮平联合碳酸锂治疗的效果对比[J].中国保健营养,2017,27(3):250.
[7]孙志国,杨巍,冯萍萍,等.广泛性焦虑症患者血清神经递质及凝血相关指标的变化分析[J].中国实用神经疾病杂志,2016,19(16):36-37.
[8]郭世锦.广泛性焦虑症患者的血清神经递质及凝血相关指标的变化情况分析[J].世界最新医学信息文摘,2016,16(31):54-55.